xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

581

Orlandi et al.

SNOT-20 improvement at 1 year (1.9 to 0.8, p < 0.01) with 91.6% patency

improvements; study did

not reach power calculation

BCD provided improvement in QoL and CT score BCD provided mean

improvements in SNOT-20 at 24-weeks maintained to 52-weeks

improvement in subjective

and objective findings at all time points

TABLE XII-16 Evidence for balloon sinus dilation Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions Bikhazi 2005 Cutler 2006 2013, 2014 2 Individual RCT BCD(n = 50) vs ESS (n = 42); CRS/RARS with minimal maxillary and ethmoid disease only, SNOT-20, 1-year follow up BCD is as effective as ESS in treatment of CRS with maxillary disease with or without anterior ethmoid disease Achar 2004 2012 3 Individual RCT BCD(n = 12) vs ESS (n = Payne 2003 polyp disease excluded

Sinus surgery utilizing BCD had significantly greater

QoL improvements than

medical management alone

improvement in SNOT-20 and RSI at 1 year

BCD yielded improvement in SNOT-20 at all time points and LM at 24-weeks

Both groups with similar

BCD provided significant

BCD provided significant

BCD provided significant

clearance time at 6-, 12- and 24-weeks

SNOT-20, LM scores at 3-6months SNOT-20/RSI at

SNOT-20 at 2-, 8-, 24-, and 52-weeks

SNOT-20, endoscopy, LM scores at 1-, 6-, and 12-months

Chronic sinusitis survey score,

SNOT-20, RSDI at 24-weeks and 52-weeks

1-month, 6-months and 1 year

SNOT-20 at 1-year

SNOT-20 at 1-, 4-, 24-, and 52-weeks LM at 24-weeks

SNOT-20, saccharine

LM scores at 24-weeks Safety, patency,

continued medical management (n = 52),

CRS without nasal polyps (n = 13) CRS or RARS (n = 81),

procedure (n = 146) vs

BCD + / − adjunctive

CRS (n = 122 at 1 year),

CRS (n = 20), limited

CRS (n = 175), polyp

CRS (n = 37), polyp

limited polyp disease included

polyp disease included

12); patients with polyps excluded

Limited polyp disease included

polyp disease excluded

disease included

disease included

Abreu 2007 2014 4 Prospective cohort study

Raghunandhan 2009 2013 4 Prospective cohort study

Karanfilov 1797 Sikand 1798 2013, 2015 4 Prospective cohort study

2016, 2018 4 Prospective cohort study

Gould 1799 2014 4 Prospective cohort study

Brodner 2008 2013 4 Prospective cohort study

Albritton 1796 2012 4 Prospective cohort study

Stolovitzky 2002